RenovoRx CEO Shaun Bagai to Participate at Major Healthcare Forum
RenovoRx, Inc., a life-sciences company dedicated to developing cutting-edge oncology therapies, is preparing for an impactful presence at the upcoming Canaccord Genuity MedTech, Diagnostics & Digital Health & Services Forum. Scheduled for November 20, 2025, the event will showcase the latest advancements in the healthcare sector and provide a platform for discussing significant industry developments.
CEO's Key Participation
Shaun Bagai, the Chief Executive Officer of RenovoRx, is set to share critical insights regarding the company's commercialization achievements and future strategies. His presentation aims to underline the urgent clinical needs fulfilled by RenovoCath, RenovoRx’s FDA-cleared drug delivery system, which has garnered interest from both new and established clientele.
Updates on Clinical Trials
During the forum, Mr. Bagai will provide updates on the ongoing Phase III TIGeR-PaC clinical trial. This trial evaluates the effectiveness of RenovoRx's innovative product, a drug-device combination that administers intra-arterial gemcitabine via RenovoCath to treat locally advanced pancreatic cancer.
Significant Developments in Oncology Treatment
RenovoRx is not only advancing its product candidates—such as the intra-arterial gemcitabine being studied in the TIGeR-PaC trial—but is also launching a post-marketing observational registry. This study seeks to assess long-term safety and survival outcomes for patients undergoing cancer treatments using RenovoCath technology.
Event Details
This pivotal forum will take place at the Westin New York Grand Central, providing attendees with valuable networking opportunities and the latest information on innovations in medical technologies and digital health.
Meeting Opportunities
Investors interested in connecting with Mr. Bagai during the forum can arrange for private meetings by reaching out through the appropriate contacts.
About RenovoRx, Inc.
RenovoRx, Inc. focuses on revolutionizing cancer treatment through its proprietary Trans-Arterial Micro-Perfusion (TAMP™) platform. Designed with high unmet medical needs in mind, the RenovoCath device allows targeted drug delivery directly to tumor sites while minimizing the adverse effects commonly associated with systemic treatments.
Innovative Approaches to Cancer Treatment
The RenovoCath device has already received Orphan Drug Designation for its potential application in pancreatic and bile duct cancer, granting it seven years of market exclusivity upon FDA approval of a related drug application. The ongoing clinical trials are essential to validating these innovative therapies as viable treatment options.
Commercial Expansion Efforts
Following the initial commercial orders for its RenovoCath devices, RenovoRx has seen enthusiastic demand from several leading cancer treatment centers. This indicates strong market prospects for the company's technology, which is tailored for precision medicine approaches in oncology.
Conclusion
As the healthcare landscape continues to evolve, RenovoRx remains committed to enhancing patient care through its groundbreaking oncology solutions. With continued progress in clinical trials and an increasing client base, the company is poised to make significant contributions to the medical community.
Frequently Asked Questions
What is RenovoRx's main focus?
RenovoRx focuses on developing targeted oncology therapies and innovating drug delivery systems to improve outcomes for cancer patients.
Who is Shaun Bagai?
Shaun Bagai is the Chief Executive Officer of RenovoRx, overseeing the company's strategic direction and product development initiatives.
What is the Canaccord Genuity Forum?
The Canaccord Genuity Forum is an event dedicated to discussing advancements in MedTech, diagnostics, and health services, bringing together industry leaders and stakeholders.
What is the TIGeR-PaC trial?
The TIGeR-PaC trial is a Phase III clinical study that evaluates an innovative drug-device combination for treating locally advanced pancreatic cancer.
How does RenovoCath work?
RenovoCath is a patented drug-delivery device designed to administer localized therapy directly to tumors, potentially reducing systemic side effects and improving efficacy.